Tang Kevin, Nastoupil Loretta J
Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Immunother Precis Oncol. 2021 Aug 5;4(3):150-159. doi: 10.36401/JIPO-21-2. eCollection 2021 Aug.
Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary treatment option for highly aggressive B cell malignancies. Clinical trials of CD19 CAR T cells for the management of relapsed and/or refractory non-Hodgkin lymphoma (NHL) have shown markedly improved survival and response rates. The goal of this review is to evaluate whether the results from these clinical trials are reflective of real-world practices through the analysis of published literature of the commercially available CAR T cell products. We have found that despite the significantly different patient characteristics, the adverse events and response rates of real-world patients were similar to those of the clinical trials. Of interest, several groups excluded from the clinical trials, such as patients with HIV infection, chronic viral hepatitis, and secondary CNS (central nervous system) lymphoma, had case reports of promising outcomes.
嵌合抗原受体（CAR）T细胞疗法已成为治疗侵袭性B细胞恶性肿瘤的一种革命性治疗选择。用于治疗复发和/或难治性非霍奇金淋巴瘤（NHL）的CD19 CAR T细胞的临床试验显示，生存率和缓解率有显著提高。本综述的目的是通过分析已发表的关于市售CAR T细胞产品的文献，评估这些临床试验的结果是否反映了实际临床实践。我们发现，尽管患者特征存在显著差异，但真实世界患者的不良事件和缓解率与临床试验中的相似。有趣的是，一些被排除在临床试验之外的患者群体，如艾滋病毒感染患者、慢性病毒性肝炎患者和继发性中枢神经系统（CNS）淋巴瘤患者，也有预后良好的病例报告。
